Company intelligence / Profile preview

EPNextS Group

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

EPNextS Group is the leading Japanese provider of integrated CRO, SMO, and CSO services, recently restructured to deliver seamless clinical trial support from early-phase (including Phase 1 in Japanese and non-Japanese populations) to post-marketing, with special expertise in bridging U.S.-Japan regulatory and operational gaps. Partners such as Frontage Laboratories extend its capabilities into early-phase U.S. trials with Japanese populations, tackling "drug lag" and "drug loss" in Japan

Industry: Contract Research Organization

Partnerships

Frontage Laboratories (U.S.), for bi-directional early-phase clinical trial executionMultiple other unnamed CROs for therapy area specialization and cross-border collaboration

Beyond the preview

Go deeper on EPNextS Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPNextS Group.

Explore the full profile